Literature DB >> 15653975

Cardiac and sternocleidomastoid muscle involvement in Duchenne muscular dystrophy: an MRI study.

Sophie Mavrogeni1, George E Tzelepis, George Athanasopoulos, Themistoklis Maounis, Marouso Douskou, Antigoni Papavasiliou, Dennis V Cokkinos.   

Abstract

OBJECTIVE: To examine the extent of cardiac muscle and sternocleidomastoid muscle (SCM) involvement detected by MRI measurement of T2 relaxation time in patients with Duchenne muscular dystrophy (DMD) and no cardiorespiratory symptoms.
DESIGN: Prospective controlled study.
SETTING: Teaching referral hospital and university hospital.
SUBJECTS: Seventeen patients with DMD (age range, 7 to 25 years) and 17 age-matched control subjects. All patients were free of cardiac or respiratory complaints and had normal ECG, echocardiograph, and Holter monitor examination findings.
METHODS: We assessed respiratory function by means of standard pulmonary function testing. MRI measurements included the T2 relaxation time of the myocardium and the SCM in patients and control subjects.
RESULTS: The FVC and FEV1 values were lower in patients with DMD than in age-matched control subjects, whereas the FEV1/FVC ratio was normal in all subjects. Patients with DMD had lower T2 relaxation time of the heart (37.8 +/- 6.1 ms vs 58.1 +/- 7.1 ms, p < 0.001) and lower T2 relaxation time of the right SCM (24.5 +/- 2.6 ms vs 42.2 +/- 1.3 ms, p < 0.001) and left SCM (23.2 +/- 3.2 ms vs 42.2 +/- 1.6 ms, p < 0.001), compared to control subjects (+/- SD). In children (< 12 years of age), the T2 of the SCM was lower than that of the control subjects, but T2 of the heart did not differ between the two groups. In the patient group, T2 relaxation time of the heart decreased with age (r = - 0.80, p < 0.001). In patients with FVC < 80% of predicted, the T2 values of the heart were lower than the T2 values of patients with FVC > or = 80% of predicted (35.6 +/- 5.8 ms vs 41.8 +/- 4.6 ms, p < 0.05).
CONCLUSIONS: MRI measurements of the T2 relaxation time in the myocardium and SCM of patients with DMD and no cardiorespiratory symptoms are abnormal, indicating altered tissue composition. These measurements may prove a clinically useful test for monitoring cardiac and respiratory muscle involvement in these patients.

Entities:  

Mesh:

Year:  2005        PMID: 15653975     DOI: 10.1378/chest.127.1.143

Source DB:  PubMed          Journal:  Chest        ISSN: 0012-3692            Impact factor:   9.410


  12 in total

1.  Cardiac magnetic resonance imaging and management of dilated cardiomyopathy in a Duchenne muscular dystrophy manifesting carrier.

Authors:  A Barison; G D Aquaro; C Passino; M Falorni; A Balbarini; M Lombardi; L Pasquali; M Emdin; G Siciliano
Journal:  J Neurol       Date:  2009-02-27       Impact factor: 4.849

2.  Myocardial inflammation in Duchenne Muscular Dystrophy as a precipitating factor for heart failure: a prospective study.

Authors:  Sophie Mavrogeni; Antigoni Papavasiliou; Kostas Spargias; Pantelis Constandoulakis; George Papadopoulos; Evangelos Karanasios; Dimitris Georgakopoulos; Genovefa Kolovou; Eftichia Demerouti; Spyridon Polymeros; Loukas Kaklamanis; Anastasios Magoutas; Evangelia Papadopoulou; Vyron Markussis; Dennis V Cokkinos
Journal:  BMC Neurol       Date:  2010-05-21       Impact factor: 2.474

3.  Left ventricular T2 distribution in Duchenne muscular dystrophy.

Authors:  Janaka P Wansapura; Kan N Hor; Wojciech Mazur; Robert Fleck; Sean Hagenbuch; D Woodrow Benson; William M Gottliebson
Journal:  J Cardiovasc Magn Reson       Date:  2010-03-18       Impact factor: 5.364

4.  T₂ mapping provides multiple approaches for the characterization of muscle involvement in neuromuscular diseases: a cross-sectional study of lower leg muscles in 5-15-year-old boys with Duchenne muscular dystrophy.

Authors:  Ishu Arpan; Sean C Forbes; Donovan J Lott; Claudia R Senesac; Michael J Daniels; William T Triplett; Jasjit K Deol; H Lee Sweeney; Glenn A Walter; Krista Vandenborne
Journal:  NMR Biomed       Date:  2012-10-09       Impact factor: 4.044

5.  Experimental models of duchenne muscular dystrophy: relationship with cardiovascular disease.

Authors:  Venus Ameen; Lesley G Robson
Journal:  Open Cardiovasc Med J       Date:  2010-11-26

6.  Magnetic Resonance Imaging Is Sensitive to Pathological Amelioration in a Model for Laminin-Deficient Congenital Muscular Dystrophy (MDC1A).

Authors:  Ravneet Vohra; Anthony Accorsi; Ajay Kumar; Glenn Walter; Mahasweta Girgenrath
Journal:  PLoS One       Date:  2015-09-17       Impact factor: 3.240

7.  Myocardial T2 mapping reveals age- and sex-related differences in volunteers.

Authors:  Florian Bönner; Niko Janzarik; Christoph Jacoby; Maximilian Spieker; Bernhard Schnackenburg; Felix Range; Britta Butzbach; Sebastian Haberkorn; Ralf Westenfeld; Mirja Neizel-Wittke; Ulrich Flögel; Malte Kelm
Journal:  J Cardiovasc Magn Reson       Date:  2015-02-06       Impact factor: 5.364

8.  Primary role of functional ischemia, quantitative evidence for the two-hit mechanism, and phosphodiesterase-5 inhibitor therapy in mouse muscular dystrophy.

Authors:  Akihiro Asai; Nita Sahani; Masao Kaneki; Yasuyoshi Ouchi; J A Jeevendra Martyn; Shingo Egusa Yasuhara
Journal:  PLoS One       Date:  2007-08-29       Impact factor: 3.240

Review 9.  Assessment and management of respiratory function in patients with Duchenne muscular dystrophy: current and emerging options.

Authors:  Antonella LoMauro; Maria Grazia D'Angelo; Andrea Aliverti
Journal:  Ther Clin Risk Manag       Date:  2015-09-28       Impact factor: 2.423

10.  Optimization of improved motion-sensitized driven-equilibrium (iMSDE) blood suppression for carotid artery wall imaging.

Authors:  Chengcheng Zhu; Martin J Graves; Jianmin Yuan; Umar Sadat; Jonathan H Gillard; Andrew J Patterson
Journal:  J Cardiovasc Magn Reson       Date:  2014-08-09       Impact factor: 5.364

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.